Flagship Ventures Fund V General Partner LLC - Jun 6, 2023 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
10%+ Owner
Signature
Flagship Ventures Fund V General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager
Stock symbol
SANA
Transactions as of
Jun 6, 2023
Transactions value $
-$2,532,858
Form type
4
Date filed
6/8/2023, 07:00 PM
Previous filing
May 26, 2023
Next filing
Aug 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Sale -$1.14M -181K -1.63% $6.31 10.9M Jun 6, 2023 By Flagship Ventures Fund V, L.P. F1, F2
transaction SANA Common Stock Sale -$141K -22.3K -1.56% $6.31 1.4M Jun 6, 2023 By Flagship V VentureLabs Rx Fund, L.P. F1, F3
transaction SANA Common Stock Sale -$1.11M -177K -1.62% $6.24 10.7M Jun 7, 2023 By Flagship Ventures Fund V, L.P. F2, F4
transaction SANA Common Stock Sale -$142K -22.8K -1.62% $6.24 1.38M Jun 7, 2023 By Flagship V VentureLabs Rx Fund, L.P. F3, F4
holding SANA Common Stock 11.4M Jun 6, 2023 By Flagship VentureLabs V, LLC F5
holding SANA Common Stock 9.73M Jun 6, 2023 By Flagship Pioneering Fund VI, L.P. F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.415, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F3 Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Each of the reporting persons except Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.36, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 Represents shares held directly by Flagship VentureLabs V LLC. ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F6 Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.